CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has commented on a recent study that indicated that cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2. The comments came from lead research scientist Dr. Richard van Breeman, who granted an interview with vice.com discussing the independent study. In his comments, Breemen observed that smoking or vaping of cannabis was likely not effective, but oral delivery was, causing Breeman to recommend oral administration of cannabis compounds. Lexaria is keenly interested in the study because the company is actively engaged in research with its exclusive DehydraTECH(TM)-powered cannabinoid formulations,…

















